Suma Krishnan Sells 13,435 Shares of Krystal Biotech, Inc. (NASDAQ:KRYS) Stock

Krystal Biotech, Inc. (NASDAQ:KRYS - Get Free Report) insider Suma Krishnan sold 13,435 shares of the firm's stock in a transaction on Monday, July 14th. The stock was sold at an average price of $150.30, for a total value of $2,019,280.50. Following the completion of the sale, the insider directly owned 1,443,276 shares of the company's stock, valued at $216,924,382.80. This represents a 0.92% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Suma Krishnan also recently made the following trade(s):

• On Wednesday, July 16th, Suma Krishnan sold 1,389 shares of Krystal Biotech stock. The stock was sold at an average price of $150.00, for a total value of $208,350.00.
• On Wednesday, July 16th, Suma Krishnan sold 1,529 shares of Krystal Biotech stock. The stock was sold at an average price of $150.00, for a total value of $229,350.00.
• On Tuesday, July 15th, Suma Krishnan sold 3,084 shares of Krystal Biotech stock. The stock was sold at an average price of $151.01, for a total value of $465,714.84.
• On Tuesday, July 15th, Suma Krishnan sold 3,036 shares of Krystal Biotech stock. The stock was sold at an average price of $150.98, for a total value of $458,375.28.
• On Monday, July 14th, Suma Krishnan sold 13,400 shares of Krystal Biotech stock. The stock was sold at an average price of $150.30, for a total value of $2,014,020.00.
• On Thursday, July 10th, Suma Krishnan sold 6,927 shares of Krystal Biotech stock. The stock was sold at an average price of $150.27, for a total value of $1,040,920.29.
• On Thursday, July 10th, Suma Krishnan sold 6,800 shares of Krystal Biotech stock. The stock was sold at an average price of $150.28, for a total value of $1,021,904.00.
• On Wednesday, July 9th, Suma Krishnan sold 200 shares of Krystal Biotech stock. The stock was sold at an average price of $150.14, for a total value of $30,028.00.

Krystal Biotech Stock Down 1.8%

NASDAQ:KRYS traded down $2.66 during trading hours on Friday, hitting $147.49. 303,976 shares of the company's stock traded hands, compared to its average volume of 287,383. The firm has a market cap of $4.26 billion, a P/E ratio of 35.45 and a beta of 0.67. Krystal Biotech, Inc. has a 52 week low of $122.80 and a 52 week high of $219.34. The business's fifty day simple moving average is $136.27 and its two-hundred day simple moving average is $156.00.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last posted its quarterly earnings data on Tuesday, May 6th. The company reported $1.20 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.38 by ($0.18). The business had revenue of $88.18 million for the quarter, compared to the consensus estimate of $98.66 million. Krystal Biotech had a net margin of 37.17% and a return on equity of 14.64%. On average, analysts expect that Krystal Biotech, Inc. will post 6.14 EPS for the current year.

Institutional Investors Weigh In On Krystal Biotech

Large investors have recently added to or reduced their stakes in the business. Raymond James Financial Inc. bought a new stake in Krystal Biotech during the fourth quarter worth about $15,989,000. Zurcher Kantonalbank Zurich Cantonalbank lifted its stake in Krystal Biotech by 31.2% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 6,054 shares of the company's stock worth $948,000 after purchasing an additional 1,440 shares during the last quarter. Swiss National Bank lifted its stake in Krystal Biotech by 8.4% during the fourth quarter. Swiss National Bank now owns 42,400 shares of the company's stock worth $6,642,000 after purchasing an additional 3,300 shares during the last quarter. Commonwealth Equity Services LLC lifted its stake in Krystal Biotech by 4.1% during the fourth quarter. Commonwealth Equity Services LLC now owns 4,866 shares of the company's stock worth $762,000 after purchasing an additional 190 shares during the last quarter. Finally, Cibc World Markets Corp bought a new stake in Krystal Biotech during the fourth quarter worth about $364,000. Institutional investors own 86.29% of the company's stock.

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on the company. Citigroup reaffirmed a "neutral" rating and issued a $176.00 price target (up from $155.00) on shares of Krystal Biotech in a report on Wednesday, July 9th. HC Wainwright reaffirmed a "buy" rating and issued a $240.00 price target on shares of Krystal Biotech in a report on Tuesday, June 24th. Guggenheim cut their price target on Krystal Biotech from $195.00 to $189.00 and set a "buy" rating for the company in a report on Wednesday, May 7th. Finally, Chardan Capital reaffirmed a "buy" rating and issued a $219.00 price target on shares of Krystal Biotech in a report on Wednesday, May 7th. One research analyst has rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of "Buy" and a consensus price target of $213.75.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).